stockrow
Friday 6 November 2026
Export STVN’s income statement to Excel — free account
Stevanato Group S.p.A.
STVN Healthcare Medical Instruments & Supplies
Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
- Revenue
- +5.91%
- EPS
- +17.5%
- Free cash flow
- +4,089.9%
- Total debt
- +2.85%
Quarter to September 2026, against a year earlier
13.51
0.30
+2.27%
Follow STVN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 6 | 5 |
+8 more TTM periods Free account |
| 9.22% | 9.21% | 9.93% | 9.88% | ||
| 5.50% | 5.46% | 5.96% | 5.86% | ||
ROIC |
6.71% | 6.56% | 6.71% | 6.84% | |
Return on Tangible Assets |
7.42% | 7.33% | 7.72% | 7.77% | |
Average Days of Receivables |
107.53 | 107.02 | 101.93 | 108.69 | |
Free Cash Flow per Share |
(0.03) | (0.13) | (0.04) | 0.05 | |
Free Cash Flow |
(8.79) | (34.67) | (10.20) | 14.60 | |
Capital Expenditures |
(297.97) | (318.84) | (317.04) | (309.07) | |
| Other line items | |||||
Cash ROIC |
(0.35%) | (1.43%) | (0.41%) | 0.61% | |
Accounts Receivable Turnover |
3.69 | 3.73 | 3.89 | 3.37 | |
Accounts Payable Turnover |
3.89 | 3.66 | 3.65 | 3.48 | |
Inventory Turnover |
3.07 | 3.01 | 3.19 | 3.35 | |
Average Days of Payables |
100.15 | 107.52 | 109.91 | 114.09 | |
Days of Inventory on Hand |
123.57 | 129.82 | 127.20 | 116.23 | |
Tax Rate |
(0.31) | (0.30) | (0.27) | (0.26) | |
Research and Development Expense of Revenue |
1.93% | 2.09% | 2.11% | 2.14% | |
Selling, General and Administrative Expense of Revenue |
10.43% | 10.56% | 10.78% | 10.78% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
22.45 | 18.58 | 10.07 | 8.77 | |
Operating CF/Net income |
1.78 | 1.82 | 1.88 | 2.05 | |
Depreciation/Fixed assets |
0.06 | 0.06 | 0.06 | 0.06 | |
Capex/Depreciation |
(2.68) | (2.92) | (2.95) | (3.08) | |
Revenue per Share |
5.29 | 5.22 | 5.10 | 4.92 | |
Operating CF per Share |
1.06 | 1.04 | 1.12 | 1.19 | |
Capex per Share |
(1.09) | (1.17) | (1.16) | (1.13) | |
Capex to Sales |
0.21 | 0.22 | 0.23 | 0.23 |
Columns are period end dates · fundamentals updated 5 Nov 2026